# Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease

> **NCT03587272** · PHASE2 · RECRUITING · sponsor: **Robert Nickel** · enrollment: 100 (estimated)

## Conditions studied

- Sickle Cell Disease

## Interventions

- **DRUG:** Alemtuzumab, low dose total body irradiation, Sirolimus

## Key facts

- **NCT ID:** NCT03587272
- **Lead sponsor:** Robert Nickel
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2018-04-17
- **Primary completion:** 2030-11
- **Final completion:** 2030-11
- **Target enrollment:** 100 (ESTIMATED)
- **Last updated:** 2026-03-10

## Collaborators

- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03587272

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03587272, "Minimizing Toxicity in HLA-identical Sibling Donor Transplantation for Children With Sickle Cell Disease". Retrieved via AI Analytics 2026-06-25 from https://api.ai-analytics.org/clinical/NCT03587272. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*